Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation

Multiple myeloma (MM) is an incurable plasma cell neoplasia characterized by relapsed and/or refractory (R/R) disease course, which poses a major therapeutic challenge. New therapies, including BRAF V600E mutation targeting, may become a new treatment option for R/R MM. In combination with mitogen-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Čepulytė, Rūta, Žučenka, Andrius, Pečeliūnas, Valdas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584966/
https://www.ncbi.nlm.nih.gov/pubmed/33123389
http://dx.doi.org/10.1155/2020/8894031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584966/
https://www.ncbi.nlm.nih.gov/pubmed/33123389
http://dx.doi.org/10.1155/2020/8894031

Ejemplares similares